Optiscan Imaging (ASX:OIL) reveals its new microscopic medical imaging device, InVue™, which is designed to enable precision surgery by putting real-time digital pathology access directly into the hands of surgeons.
- Optiscan reveals its InVue™ next-gen microscopic medical imaging device for precision surgery.
• InVue™ expands Optiscan’s product portfolio into the surgical application market, representing a significant step forward in realising the Company’s strategic goals.
• InVue™ can be used in a variety of clinical settings, most notably in cancer diagnosis and treatment.
• InVue™ is designed to put digital pathology directly in the hands of surgeons as they operate, to enable on-the-spot decision making and treatment adjustments.
Optiscan CEO and Managing Director, Dr Camile Farah, said: “Getting our next-gen InVue™ microscopic medical imaging device to the reveal stage is a real credit to the hard work of the entire Optiscan team. The reveal is much more than just a significant milestone in the Company’s growth strategy. It paves the way for a significant evolution of digital pathology and precision surgery. InVue™ will bring digital pathology insights into the operating theatre and directly into the hands of surgeons. The end-result will be enhanced speed and accuracy of treatment, which should in turn deliver improved patient outcomes.”